Company | Key Facts

Company founded:	1997
Location:	Bernried, 50 km south of Munich
Employees:	31
	More than 1000m² laboratory and office space
Ownership:	Epidauros is owned by the global biotechnology company Clinical Data^®, Inc (NASDAQ: CLDA); Newton, Mass., USA
Business Areas:	Pharmacogenetic Services Pharmacogenetic Products
Service-related track record includes:	About 400 clinical genotyping studies performed from small scale to multicenter trials with more than 3500 patients Over 60,000 patient samples analyzed to date Portfolio > 1100 validated assays for more than 100 genes
Customers:	Broad Service-related customer base consisting of many leading pharma and biotech companies and Contract Research Organizations (CROs)
Product related activities:	Several licensing agreements in place with leading diagnostic companies
	Strategic partnership with Osmetech^® plc. to develop diagnostic products Strategic partnership in pharmacogenetic studies with PAREXEL and FOCUS for many years
Intellectual Properties:	Broad patent portfolio with 14 patents and patent applications in the fields of drug metabolizing enzymes (DMEs) and drug transporters
Professional memberships:	Epidauros represents the BPI (Association of the German Pharmaceutical Industry) in the ad hoc Pharmacogenetic Working Group of EFPIA (the European Federation of Pharmaceutical Indurstry and Associations) as one of the six ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) Members.
	Epidauros is also a member of the Steering Committee for ’Individualised Drug Therapies and Tissue Engineering’, part of the ’Task Force Pharma’ of the BMG (German Federal Ministry of Health).
Epidauros´ operations:	DIN EN ISO 9001-certified GLP-compliant (OECD, German Chemicals Act) Proficiency testing proven for genetic assays (DGKL-RfB)